NRGN and Alzheimer disease: Given the relatively high variability of Ng levels in the control and AD groups, our study should be seen as a pilot study, to be confirmed with higher sample numbers with both clinically and biochemically characterized AD and control samples, ideally by ELISA methods targeting directly only full‐length Ng and either N‐terminal or C‐terminal fragments along with full‐length Ng.